Carpal Tunnel Release Systems Market: Open CTR Systems to Remain Largest Product Type Through 2028

Increased awareness among patients suffering from carpal tunnel syndrome, apropos of carpal tunnel surgeries is projected to drive the global market for carpal tunnel release (CTR) systems, over the forecast period of 2018-2028. Moreover, the success rate of carpal tunnel release procedures would also fuel the demand for carpal tunnel release systems through 2028.  Future Market Insights (FMI), in its recently released intelligence outlook on the global market for carpal tunnel release systems, forecasts steady growth for the market over the next 10 years.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-5965

During 2018-2028, the global revenue of carpal tunnel release systems market is anticipated to expand at a steady CAGR of 5.5% and reach a market valuation worth US$ 839.1 Mn by the end of 2028. The Endoscopic CTR systems segment is expected to grow at a high CAGR compared to open CTR systems throughout the forecast period. The demand for carpal tunnel release systems is primarily emanating from North America, followed by Western Europe—both also holding the maximum revenue share in the global CTR systems market. Affordable and better equipped emergency rooms are contributing to the growing demand for better quality surgical procedures. Increasing geriatric population in China and Japan would open new market opportunities for carpal tunnel release system manufacturers looking to expand their business footprint.

Efficient, Evolved Surgery Procedures Fuelling Carpal Tunnel Release Systems Adoption

In the last few years, there has been an increase in carpal tunnel surgeries performed on out-patient surgeries owing to lower healthcare expenditure and better medical reimbursement coverage. This demand for carpal tunnel surgeries is attributable to the availability of effective and efficient products meant for CTR procedures. Key manufacturers of carpal tunnel release systems are collaborating with contract manufacturing organizations for developing efficient products according to treatment requirements. In terms of surgery methods, although cost-effective open surgical procedure for carpal tunnel release was previously the most preferred, efficiency and less risk associated with endoscopic procedures has led to an increased investment in this method, with key players like Stryker Corporation and Arthrex launching their range of endoscopic carpal tunnel release systems. Evolution of CTR surgeries with endoscopic methods has boosted the overall growth of carpal tunnel release systems market.

“Risks associated with carpal tunnel release surgeries could inhibit the growth of CTR systems to some extent. Nerve injury is the major risk associated with open surgery. Moreover, both, open and endoscopic methods have technical limitations. The invasive nature of both these methods and emergence of alternatives which do not require any incision would result in sluggish adoption of carpal tunnel release systems in the coming years”, Analyst, Healthcare Industry, Future Market Insights

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-5965

Acquisition, Product Innovation: Key Forward Strategy to Define Future Market Positions of Manufacturers

Leading manufacturers in the carpal tunnel release systems market are focusing on acquiring local manufacturers to expand their product portfolio and increase market share, developed and emerging markets. Manufacturers are also collaborating with hospitals and distributors to promote their CTR systems and expand regional presence, respectively. Increased research and development for a more focused product innovation and product enhancement would also drive the global carpal tunnel release systems market over the forecast period. Key manufacturer in the carpal tunnel release systems market are Arthrex, Smith & Nephew, CONMED Corporation, Integra LifeSciences Corporation, MicroAire Surgical Instruments, S.E.G-WAY Orthopaedics, Thayer Intellectual Property, and Sonex Health, LLC

Analgesics Market will reach at a CAGR of 5.3% from 2018 to 2028

By drug class, opioids are widely used analgesic drugs for treating moderate to severe pain such as pain caused by surgery, cancer, trauma, injury, and other diseases. Owing to their high efficiency and widespread availability in the developed markets of North America and Western Europe, opioids are a high revenue generating segment in the global analgesics market. In a new research publication, leading market research firm Future Market Insights presents forecasts on revenue generated from the sales of branded and generic analgesic drugs including opioids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and local anaesthetics.

According to Future Market Insights’ projections, the global prescription analgesics market is anticipated to reach a whopping US$ 79 Bn by 2028 end, up from an estimated US$ 47.5 Bn in 2018. This is indicative of a CAGR of 5.3% during the 10 year period from 2018 to 2028. This growth is mainly contributed by the regional markets in North America and Western Europe that are projected to collectively hold a revenue share of just under 71% in 2018.

Commercialization of Abuse Deterrent Opioid Drugs to Provide Lucrative Growth Opportunities to Pharmaceutical Majors in the Analgesics Market

Following the U.S opioid crisis, several countries across the globe are introducing regulations pertaining to the prescription of opioids. To curb the growing abuse of painkilling drugs, pharma companies are introducing different types of abuse deterrent drugs in the global market. Opioids are widely used for pain management in North America and Europe and are being increasingly used for non-medical purposes as well. Government organizations in these economies are encouraging doctors to prescribe non-opioid analgesics. This is slated to create significant growth opportunities for companies to introduce novel non-opioid drugs in these markets. The situation in the countries of Asia and Africa is different – the limited availability of both opioid and non-opioid drug delivery systems for pain management provides immense opportunities to manufacturers of analgesics for regional market penetration.  

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1306

Opioid intolerance is a new phenomenon that has hit the pharmaceuticals industry in North America and Europe. Opioids are ineffective in treating certain cases of severe pain, necessitating patients to take higher doses to alleviate the pain. This eventually makes them opioid intolerant or addicted to these drugs. Commercializing opioid tolerant drugs is the most viable solution that will help reduce the side effects associated with increasing consumption of opioids. Manufacturers in the global analgesics market are expected to benefit from the numerous opportunities presented by the commercialization of opioid tolerant drugs.

Development of Non-opioid Extended Release Drugs and Commercial Expansion via Novel Product Approvals to Fuel Revenue Growth

Key players in the global analgesics market are focused on R&D initiatives to develop non-opioid drugs using innovative drug delivery approaches to facilitate extended release of the medication, which can provide pain relief for a longer time duration. Pharmaceutical companies are also launching cost-efficient opioid drugs in Asian countries and this is expected to boost revenue growth in the global market for analgesics. Commercial expansion of products across potential growth markets in Asia and Africa is a feasible strategy being adopted by manufacturers of analgesics to expand their global market footprint.

Reimbursement for Palliative Care and Opioid Consumption Trending the Global Market

Opioids are largely used in palliative care for treating terminally ill patients. There is a growing focus on palliative care services across third world countries. This – coupled with readily available reimbursement options – is expected to boost the consumption of opioids in the coming decade. Several government initiatives to promote palliative care among patients suffering from cancer pain in low and middle income countries are promoting the adoption of opioids as an effective pain management solution.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1306

Another trend being observed in the global market is the use of Opioids Maintenance Treatment (OMT) to treat Opioids Dependence (OD). The main objective of OMT is to reduce patients’ addiction to consume illicit drugs that are used to reduce opioid dependency. While there are certain controversies associated with the commercialization of OMT (it is claimed that OMT is another form of addiction), these drugs are highly regulated and the concerned governments are implementing stringent regulations to prevent abuse of these drugs.

Sports Medicine Market: North America to Lead the Global Market in Terms of Revenue

Sports medicine, an upcoming healthcare field, involves the treatment of various injuries related to sports along with athlete evaluation with a view to improve the athletic performance. Sports sector has witnessed large participation of population in sports. The growth of the sports medicine market can be primarily attributed to the increasing sports injuries. Another aspect that is pushing the growth of the global sports medicine market is the growing technological advancements in the medicine and medical devices sectors that is introducing new products in the market. This has triggered the adoption of sports medicine by consumers on a large scale, thus widening its scope in various application areas. Moreover, influx of new modalities coupled with innovations in the field of regenerative medicine and allografts have contributed to the growth of the global market for sports medicine in recent years. Increasing number of players in the sports medicine, penetration of large players in this field, growing government support and increasing awareness are set to drive the growth of the sports medicine market. However, high prices are associated with sports medicine, especially orthopaedic implants which is challenging the growth of the global market.

The comprehensive research report on “Sports Medicine Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2022)”, skilfully crafted by Future Market Insights reveals various aspects of the global sports medicine market along with key product types and applications, the analysis of which can be used to achieve expansion milestones in the years to come. As per sports medicine market research study, projection is that the market is expected to expand at a robust CAGR of 7.4% throughout the 2017-2022 period of assessment.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-5173

4 Key Highlights on Global Sports Medicine Market

The global sports medicine market has been segmented by product type, by application and by region.

• By application, the knee injury segment reflects high potential with respect to both market share and growth in the years to come. The prevalence of knee injuries is rising among the athlete population. This fact has called for quick and effective treatment of knee injuries, thus making it a more lucrative segment. The knee injury segment by application is anticipated to grow at the robust rate to reflect a market share of 32.3% as of 2017, thus leading the global market and this trend is anticipated to continue over the assessment period
• The shoulder injury application segment is also gaining significant traction since last couple of years. This segment is projected to grow at a 7.4% CAGR during the period of forecast to reach a noteworthy market share by 2022 end. This segment stands second in terms of market value during 2017-2022 followed by ankle and foot injuries application category
• North America is the largest and the most attractive region for the growth of the global sports medicine market pertaining to market share. The sports medicine market in North America region is projected to grow at CAGR more than 7.0% throughout the assessment period. With respect to market share, Europe stands second to North America growing at a high CAGR. Asia-Pacific excluding Japan (APEJ) region is also anticipated to show significant growth in the years to come
• Body Reconstruction segment by product type is expected to lead the global market as it reflects a high market share of more than 40% as of 2017 growing at a robust CAGR throughout the period of forecast. Body support and recovery segment is the second largest segment during the assessment period

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-5173 

Global sports Medicine Market: Competitive Scenario

The research report on global market for sports medicine has profiled several key players involved in sports medicine domain. Their detailed analysis with respect to product portfolio, company overview, recent developments and innovations, SWOT analysis and key financials has been included in this research report. Key players such as Arthrex, Inc., Smith & Nephew Plc., Stryker Corporation, CONMED Corporation, Zimmer Biomet Holdings, Inc., Mueller Sports Medicine, Inc., Wright Medical Group N.V., Medtronic Plc, Johnson & Johnson and Breg Inc., are profiled in this study.

Neurological Biomarkers Market to Reach a Valuation of US$ 8,700 Mn By 2025

Biomarkers have their own importance in the process of a therapeutic intervention. It is considered a crucial part of the drug discovery as well as the detection and cure of a disease. Neurological biomarkers is a new branch that is gaining traction in the global market. A new report by Future Market Insights depicts the progress of global neurological biomarkers market and the forecast for the upcoming years. This comprehensive research report projects the overview of global neurological biomarkers market, titled ‘Neurological Biomarkers Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2025)’. According to the report, global neurological biomarkers market is expected to showcase a significant growth in coming years with a CAGR of 5.1% during the forecast period, and reach a market value of over US$ 8,700 Mn by the end of 2025.

Global Neurological Biomarkers Market: Snapshot
The neurological biomarkers are specific to the detection or analysis of molecular mechanism taking place in a person’s neurological disorder. Though the market’s scope is restricted to just the neurological segment of a human body, it holds a huge market share in the coming years. The growth is primarily driven by the increase of neurological disorders. There is a huge increase in the rate of population suffering from disorders like Alzheimer, Parkinson, Schizophrenia, Depression and Multiple Sclerosis.  The prevalence of such diseases has also triggered the drug development practices.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-6626

Many researches are solely dedicated to development of various drugs in the market which are based on the results of biomarkers. Thus, the global neurological biomarkers market is expected to proliferate in the coming years. The market includes highest application of neurological biomarkers for Alzheimer, which is expected to hold the highest market share of over US$ 2,100 Mn in the global neurological biomarkers market. However, new application areas like Schizophrenia and Spinal Muscular Atrophy are expected to witness more attractiveness in the global market, as both the segments are expected to lead with a growth at high rate.

The report also reveals the growth to be seen majorly in Asia Pacific during the forecast period. The region is expected to gain attractiveness in the coming years, as the neurological biomarkers market finds larger area of application and grow at a CAGR of 6.1% during the forecast period.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-6626

Global Neurological Biomarkers Market: Upcoming Opportunities and Trends

Increasing prevalence of neurodegenerative disorders is expected to bolster the demand of neurological biomarkers in the global market. The growth is expected to introduce new trends in the market and help businesses capitalize on the opportunities coming their way. One of such trends is ELISA, which is a high sensitive method for detecting proteins in complex matrices such as urine, serum, plasma and saliva. It is considered as the best available method for quantification of proteins, and is also expected to gain traction in the coming years.  The major players that are behind introduction of such trends in the market and are also ruling the global neurological biomarkers market are Quanterix Corporation, Qiagen N.V., Thermo Fisher Scientific Inc. ADx Neurosciences NV, Merck KGaA., Acobiom, Banyan Biomarkers, Olink AB INC., Bio-Rad Laboratories, EuroImmun AG (Sub. PerkinElmer) etc.  There are many more trends in the market like mass spectroscopy and integrative biology. The coming years will project clear picture of the trend that will stand out and lead as a significant driver of global neurological biomarkers market.

Prurigo Nodularis Treatment Market to expand at a steady CAGR of 4.8% by 2028

According to the latest report published by Future Market Insights titled ‘Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028’, the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018–2028. The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018–2028.

Global Prurigo Nodularis Treatment Market: Factors Influencing Growth

Favourable regulations and initiatives for orphan drug development in various regions is expected to fuel the market for prurigo nodularis treatment in the near future. The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-3339

Global Prurigo Nodularis Treatment Market: Segmental Insights

The global prurigo nodularis treatment market has been segmented on the basis of product type, distribution channel and region. Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.  Globally, capsacin cream under the product type segment stands the most attractive product form amongst the different product types. Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.

Global Prurigo Nodularis Treatment Market: Regional Highlights

With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region. Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis. North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate. Eastern Europe is projected to be the third largest market for prurigo nodularis treatment.

Key Research Findings

• The global prurigo nodularis treatment market is expected to create incremental opportunity of US$ 197.9 Mn between 2018 and 2028
• The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3339

Global Prurigo Nodularis Treatment Market: Vendor Insights

The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market. Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others. In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.

Membrane Microfiltration Market to Cross US$ 8 Bn by 2028

Several traditional techniques such as pasteurisation, heat treatment, and sterilisation have long been used to improve the shelf life of milk. One of the newest alternatives to heat treatment is microfiltration that reduces bacteria and improves the shelf life of dairy products, while also preserving the basic taste. Adoption of membrane microfiltration in milk is one of the trends being witnessed in the global market, according to a new research study on the global membrane microfiltration market by Future Market Insights. An increasing adoption of ceramic microfiltration membranes for cross flow filtration in water plants is another key trend, as ceramic membranes help maintain a high filtration rate and ensure enhanced savings in membrane replacement costs.

Manufacturers in the membrane microfiltration market are producing robust microfiltration systems using large filter cartridges that occupy lesser space and eliminate the number of filtration system connections, thereby reducing maintenance costs. A preference for continuous fermentation over batch processing is also being observed, with manufacturers increasingly deploying membrane microfiltration technology in their plants. These trends are likely to positively impact revenue growth of the global membrane microfiltration market in the coming years. According to Future Market Insights forecasts, sales revenue in the membrane microfiltration market is anticipated to cross US$ 8 Bn by 2028, from an estimated value of about US$ 3.8 Bn in 2018. A decadal growth rate of 7.8% can be attributed to several factors, of which Future Market Insights throws deeper insights in this research study.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-5402

Increasing Applications in Industrial Biotechnology and Widespread Use of Large Molecule Biopharmaceuticals Pushing Revenue Growth of the Global Membrane Microfiltration Market
Membrane microfiltration is finding application in the production of biofuel and bio refineries are incorporating this technology to lower the overall energy costs and reduce industrial bio waste. Membrane microfiltration is also increasingly used in biodiesel processes where this technology is used to reuse water especially in areas of water scarcity. The rising industrial applications of membrane microfiltration are fuelling revenue growth in the global market. Also, filtration is a critical component of biopharmaceuticals production, and membrane microfiltration is widely used to remove cellular debris and other cellular colloids. With a growing adoption of large molecule biopharmaceuticals owing to their therapeutic properties, the demand for membrane microfiltration technology in the production of biopharmaceuticals is expected to surge in the near future.

Membrane microfiltration is also extensively used in the food and beverages industry as a technology to separate and purify components and improve the quality and yield of food products. An increasing use in vegetable and fruit juices, fermented dairy products, milk and dairy products, non-alcoholic beverages, and other food and beverage products is expected to spur revenue growth of the global membrane microfiltration market to a significant extent. One of the other critical application areas of membrane microfiltration is in water treatment plants. Membrane microfiltration helps remove unwanted particles from water before the water is treated for purity using other processes such as reverse osmosis. A growing need for quality potable water is further driving growth of the membrane microfiltration market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-5402

Future Market Insights Recommends…

With newer applications of membrane microfiltration coming to the fore, Future Market Insights feels there is a great deal of opportunity for key players operating in the global market. Water treatment and food and beverages are two important end-use application areas that manufacturers can target with their advanced solution offerings. China is projected to be the fastest growing regional market for membrane microfiltration in terms of demand for the technology, and manufacturers would be well advised to focus on this region to augment their market share. By setting up robust supply chains in regions that are anticipated to develop at a faster pace in the coming years, manufacturers can benefit from the lucrative opportunities presented by local markets to up their current standing in the global membrane microfiltration market.

Will Implantable Bioartificial Kidneys Eradicate the Need for Dialysis in Patients with Renal Failure?

Patients with end-stage renal disease (ESRD) currently have two treatment options – kidney transplant and dialysis. The limited number of kidney donors worldwide and the various medical complications that arise from dialysis have pushed the medical fraternity to look for suitable alternatives to treat ESRD. Implantable bio artificial kidneys are the latest innovation in healthcare science that provide the health benefits of kidney transplantation and potentially wipe out the need for dialysis. Powered by silicon nanotechnology, artificial kidneys seek to eliminate the torture faced by dialysis patients and may prove to be a boon to patients with acute renal failure.

In a new development, the Kidney Research Institute of the University of Washington is currently developing a wearable artificial kidney that is expected to go into clinical trials in 2022. This could be a game changer in the medical devices sector, and may reduce the dependency on dialysis equipment to a great extent.
To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-711

Dialysis Continues to Remain Dominant Therapy to Treat ESRD

While developments in the global healthcare sector continue to focus on innovative products and therapies, dialysis is currently the most administered treatment option for ESRD. Dialysis equipment is in great demand in hospitals, clinics, and dialysis centres across the world, boosting demand in the global market. According to a recent research study published by Future Market Insights, the global dialysis equipment market is projected to register a CAGR of 4.8% and will likely reach a valuation of US$ 23.6 Bn by 2028 end. The medical sector meanwhile continues to introduce newer dialysis equipment in the global market to address the varied needs of patients.

Portable Home Dialysis Equipment Trending the Global Market

Home dialysis has remained a preferred option for patients with renal disease as it is more convenient and less expensive than hospital based dialysis. Leading medical devices manufacturer Quanta has recently launched advanced haemodialysis equipment with an objective to improve the lives of patients requiring dialysis on a regular basis. This is an extremely flexible dialysis treatment that patients can take in the comfort of their homes. Quanta’s home dialysis equipment is portable, lightweight, and very easy to use. This dialysis equipment also incorporates advanced technology such as high-res screens with touchscreen functionalities and helps enhance patient outcomes.

Manufacturers of dialysis equipment are developing fully automatic, portable, and advanced dialysis equipment to treat patients of all ages suffering from ESRD. A notable technological advancement includes the introduction of high-efficiency and high-flux membranes, enabled by technical advances in membrane technology and polymer chemistry. Unlike traditional renal replacement machines, automated dialysis equipment facilitates the management of disease parameters digitally, thereby ensuring more accuracy and reducing costs of labour.

Wearable Dialysis Equipment to Ease Patient Discomfort; Expected to Rule the Global Market

With technology having proliferated every aspect of human lives, the innovation of wearable dialysis equipment is a blessing for countless dialysis patients, who can now break the shackles of confinement to fixed dialysis equipment and enjoy increased mobility. Wearable dialysis equipment is a miniature artificial HD machine based on dialysate regenerating sorbent technology. Designed for use as a belt, patients can wear this dialysis equipment for slow, gentle dialysis. This dialysis equipment is touted to best mimic the natural kidney function of blood cleansing. Given the continuous advancements taking place in medical device technology, wearable dialysis equipment may soon emerge in a more compact and small form factor to provide increased convenience and usability to patients.

Miniature artificial kidneys could redefine the entire ecosystem of dialysis treatment. The integration of portable home haemodialysis equipment facilitating elongated use in homes and offices with wearable artificial kidneys for peritoneal dialysis allowing uninterrupted blood cleansing throughout the day will ensure more patient comfort and guarantee better and enhanced performance of the dialysis equipment.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-711

The dialysis equipment market is expected to witness significant innovations in the coming years. Whether an upgrade to existing dialysis equipment or a viable alternative to dialysis itself, new-age dialysis equipment will promise increased mobility, less trauma, more peace of mind, and reduction in the burden of healthcare costs. 

Event Management Software Market to expand at a steady CAGR of 12.1% by 2026

Companies have begun the usage of event management software as it helps in improving the efficiency of the events business. The significant features of this software helps in powering successful events for industries as well as organizations of all sizes.

Global Market for Event Management Software: Dynamics Influencing Revenue Growth

With regards to revenue, the software segment is the most significant segment in the global event management software market and is projected to attain a market value of greater than US$ 5,000 Mn in 2017. Apart from this, software segment is expected to display substantial revenue growth owing to the increase in the adoption of professional services by corporate companies. The improved benefits of event management software is the key factor enhancing the adoption as well as growth of the software segment over the predictable period.

Social media platforms are turning out to be the most popular way for promoting as well as marketing events, social causes, campaigns, etc. The registration process is supported by software segment and people who visit the particular page on Facebook will be provided with e-ticket on their smartphone by the event management software. The e-ticket just has to be shown in the venue and entry will be given soon after the formalities of payment is done, which is either through cash or online payment. The ease and convenience of this process is also an important factor that eventually drives the market. Additionally, increase in the adoption of cloud-based solutions due to ease in accessibility and cost-efficiency is also aiding to the growth of software segment. All of these factors together are producing robust development in the global market for event management software’s software segment.

Request for sample copy of report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1849 

Taxonomy of Global Market for Event Management Software

The segmentation of the global market for event management software is done on the basis of enterprise type, deployment type, component type, industry type as well as region.

On the basis of enterprise type, the global market for event management software is segmented into large, medium and small enterprise. On the basis of deployment type, the global market for event management software is segmented into cloud and on-premise. Depending on the component type, the global market for event management software is segmented into software and services. Based on the sub-segment, software is segmented further into analytics and reporting, venue management, event marketing, event planning and others. Based on the sub-segment, services is segmented further as managed services and professional services. On the basis of industry type, the global market for event management software is segmented into travel and hospitality, education, government, event planner, corporate and others. On the basis of region, the global market for event management software is segmented into MEA, Japan, APEJ, Eastern Europe, Western Europe, Latin America and North America.

Regional Analysis

The market for event management software in North America is expecting that revenue from its software segment to upsurge at a reasonably high CAGR throughout the forecast period. Also, in this segment, the sub-segment namely event planning, is projected to upsurge at a high revenue CAGR throughout the forecast period. In Latin America, the sub-segment namely professional services is expected to expand at a high revenue CAGR throughout the projected period. In APEJ region, due to increase in the adoption of event marketing and venue management solutions, the software segment’s revenue is anticipated to upsurge at a high CAGR. The market for event management software in MEA is expecting that revenue from its software segment to upsurge at a reasonably high CAGR. This expectation is based on increase in the adoption of software for online event organizing, online registration, event planning and others.

Request to view Table of Content @: https://www.futuremarketinsights.com/askus/rep-gb-1849

Competition Landscape of Global Market for Event Management Software

The extensive research report on the global market for event management software covers analysis on the major companies active in the global market for event management software. Key companies such as SocialTables, EventZilla, Gather Technologies Inc., Certain, Inc., Zerista, Ungerboeck Software International, Bizzabo Inc., EventBrite Inc., etouches Inc., Zoho Corporation, Cvent, Inc., and Xing Events are profiled in this research report.

Diabetes segment market revenue share projected to grow at a significant CAGR owing to increasing prevalence of diabetes in Asia Pacific and MEA regions

Differential and innovative product strategies that are adopted by various multinational pharma companies have been fuelling the growth of branded generics market at a global scale. These strategies include establishing sustained local capabilities with the strong local talents, engaging in portfolio marketing, recalibrating regulatory affairs, bolstering sales force with the multi-channel engagement and enhancing contracting capabilities. Developing regions are witnessing a rapid increase in demand for branded generics on account of increasing affordability of the products and ease of regulations. Rising disposable income and changing lifestyle of consumers is also expected to augur well for growth of the branded generics market in the near future.

The study predicts that patent expiries of the blockbuster drugs are likely to create demand for branded generics during the forecast period. Increasing prevalence of the lifestyle and chronic diseases such as cardiovascular diseases and diabetes together with increasing purchasing power makes branded generics market attractive for investors. The study by Future Market Insights predicts that branded generics market is likely to register a healthy 7.3% CAGR over the forecast period, 2016-2026. Commodity generic products and huge competition from the branded drugs have prevailed as major challenges inhibiting the growth of branded generics market, in terms of price structure.

Request for sample copy of report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1260 

Cardiovascular Diseases are likely to prove highly lucrative for revenue growth of branded generics market due to rising prevalence of diverse types of cancers and increasing comorbidities across the globe. Anti-hypertensive segment is expected to prove highly lucrative for the purpose of reducing premature cardiovascular disease. Oral formulations hold the largest demand from medical providers and patients for branded generics. This is mainly due to the benefits that oral formulation offers such as accuracy, dosing convenience and easy adherence to a medication plan.

Parenteral formulations are likely to gain traction in branded generics market during the forecast period, with API (active pharmaceutical ingredient) being degraded in intestinal tracts, thereby driving the demand for parenteral delivery. The report predicts that APEJ and North America are likely to remain lucrative for parenteral formulations during the forecast period. Retail Pharmacies are expected to prove as the most lucrative distribution channel for branded generics, as the pharmaceutical companies’ manufacturers are highly dependent on this distribution channel for selling the products over-the-counter.

APEJ accounts for the largest revenue share in the branded generics market owing to lack of worldwide health coverage and higher out-of-the-pocket expenditure on healthcare. China, India and ASEAN countries are expected to pose lucrative growth opportunities for the new and existing key players in the forthcoming years. Most of the leading manufacturers in the global market are concentrated in Asian countries and have been working towards expansion of their production capacity, for catering to the existing and emerging global demands.

Statutory regulatory bodies have been playing a significant role in the growth branded generics market in APEJ by providing approvals for products. Furthermore, growth through the adoption of inorganic approaches have been forming cornerstone of the branded generics drug makers in APEJ region. Latin America, Eastern Europe and North America will prove significantly lucrative for the branded generics market in the forthcoming years.

Request to view Table of Content @: https://www.futuremarketinsights.com/askus/rep-gb-1260

Brand-name prescriptions are anticipated to remain ubiquitous amongst the aged people worldwide. Since geriatric demographics hold a larger portion of drug-consuming population across the globe, demand for branded generics are expected to rise substantially. Branded generics market has been projected to develop at a healthy pace as enormous number of the pharmaceutical products are expected to go off-patent within the assessment period of 2016-2026.

Pharmaceutical Filtration Market Would Reach US$ 17 billion by 2022

Active pharmaceutical ingredients are a key component of the pharmaceutical industry in the 21^st century. Filters are essential in a number of cases during the course of API creation and are necessary in bioscience laboratory applications as well. An increased production of large biologics and molecules, nano fibre technological advancements, generic market growth, and regulatory guidelines for cleanroom pharmaceutical production are the main factors driving the pharmaceutical filtration market. Additional funds diverted towards R&D expenditure by major biopharmaceutical organizations also boost the profile of the pharmaceutical filtration market. According to Future Market Insights, the pharmaceutical filtration market is expected to record a robust CAGR of 6.1% for the period from 2017 to 2022.

• Manufacturing has the major portion of the revenue share in the pharmaceutical filtration market by operation in 2017 and is likely to remain so throughout the duration of the forecast period. The manufacturing segment is expected to cross a value of more than US$ 9.3 billion by end 2022 making it imperative for companies to be present in this operation segment of the pharmaceutical filtration market. The pilot scale segment follows at a considerable distance but cannot be overlooked entirely in favour of manufacturing. The pilot scale filtration segment has strong scope in North America as the continent represents a little over a third of the pharmaceutical filtration market and is estimated to retain this share going forward
  

Request for sample copy of report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-5028

• The cell separation segment comprises slightly above a sixth of the pharmaceutical filtration market by application and is predicted to lose popularity in the future. Nonetheless, the North America cell separation market alone is on track to push past a billion dollars by end 2022 and companies are advised to take this into account while devising their business strategies. The water purification segment has a similar revenue share to the cell separation segment in the pharmaceutical filtration market by application. After North America, the water purification segment is particularly prominent in Europe
  
• In terms of technology, microfiltration is quite popular as it contributes nearly half the revenue share in the pharmaceutical filtration market in the year 2017. Furthermore, microfiltration is anticipated to witness a high CAGR of more than 5.5% for the period 2017-2022 ensuring that all key stakeholders have ample opportunity in this lucrative technology. Ultrafiltration is not as prominent as microfiltration in the pharmaceutical filtration market but is gaining traction recently. Ultrafiltration technology has the greatest scope in both North America and Europe as these two continents are projected to cross a billion dollars in terms of value by end 2022
  
• North America is the largest region in the pharmaceutical filtration market and is poised to grow to more than US$ 6 billion by end 2022
  

Request to view Table of Content @: https://www.futuremarketinsights.com/askus/rep-gb-5028

• The report has profiled a few of the companies in the pharmaceutical filtration market. These include The Marmon Group LLC, Sartorius Stedim Biotech, Meissner Filtration Products, Parker Hannifin Corporation, Pall Corporation, Merck KGaA, GE Healthcare Inc., Eaton Corporation Plc., Amazon Filters Ltd., and 3M Companies.
  

Empty Capsules Market: Increased demand for vegetarian empty capsules in developing markets to create significant revenue traction

Steady increase in the number of photochemically unstable drugs will continue to positively influence the growth of the empty capsules market in 2016, with global revenues expected to increase by 6% to reach US$ 1,432.6 Mn. 

Increasing demand for vegan and Halal pharmaceuticals is ramping up adoption, and providing support to a market, which is primarily driven by Type-A (pork-based) capsules. Development of hypromellose capsules for the treatment of pulmonary and non-pulmonary diseases are also creating growth opportunities for manufacturers.

Gelatin-based capsules will continue to account for higher demand than vegetarian-based capsules, accounting for nearly 71% revenue share of the market in 2016.  Type-A (pork skin), the largest segment in terms of raw materials, will grow at a lower rate than non-pork based empty capsules, especially hydroxy propyl methyl cellulose (HPMC) and fish bone gelatin. While type-A (pork skin) revenues will grow by 4.62% in 2016, fish bone gelatin and HPMC revenues will grow by 8.87% and 8.40% respectively.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-782  

Size “4” capsules will continue to be the largest revenue segment on the basis of capsule size, with total revenues expected to reach US$ 263.1 Mn in 2016. Size “1” and Size “2” capsules will also account for substantial demand, collectively accounting for over US$ 430 Mn in market revenues in 2016.

Empty capsules are administered orally, and only a small percentage of these drugs is inhaled – the former accounted for 91.1% revenue share of the global market in 2015. While inhalation-based empty capsules will grow at a higher rate, they will continue to account for a revenue share of less than 10% of the overall market.

Pharmaceutical companies – the largest end-use segment for empty capsules – will continue to post strong gains in 2016. Revenues from this segment are anticipated to increase at 5.79% in 2016 to total US$ 940.8 Mn. Demand will also be healthy in the cosmetics and nutraceutical sector, with this segment collectively accounting for nearly US$ 360 Mn in revenues in 2016.

The U.S. is the largest market for empty capsules, with total revenues expected to reach US$ 500 Mn in 2016. The North America empty capsules market (U.S. and Canada) is the largest globally in terms of revenues, accounting for nearly 43% revenue share of the market. Western Europe will maintain its position as the second largest market for empty capsules, with total revenues expected to reach US$ 279.4 Mn in 2016. Germany and France are the two largest markets in terms of revenues, with the former accounting for the highest revenue share and the latter growing at the highest rate.

Key players in the global empty capsules market included include Capsugel, ACG Worldwide, CapsCanada Corporation, Roxlor LLC, Qualicaps, Inc., Suheung Co., Ltd., Medi-Caps Ltd., Sunil Healthcare Ltd., Snail Pharma Industry Co., Ltd. and Bright Pharma Caps, Inc.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-782

Long-term Outlook: The global empty capsules market is anticipated to increase at a CAGR of over 7% to reach US$ 2,902.5 Mn in revenues by 2026.

Digital Pathology Market: Increasing Adoption in Cancer Research and Diagnosis to boost the market for Digital Pathology Scanning

Future Market Insights (FMI) recently announced the release of its report titled “Digital Pathology Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2025.” According to the report, the global digital pathology market, estimated to be valued at US$ 326.7 Mn in 2015-end, is expected to expand at over 11% CAGR to total US$ 954.4 Mn by 2025.

According to FMI’s report, growing need for real-time access to pathology outcomes is a key factor fuelling widespread adoption of digital pathology services. Increasing initiatives by pharmaceutical companies to develop novel medicines for cancer treatment has also contributed to increase the scope of digital pathology systems.

Adoption of digital pathology services and solutions is anticipated to witness robust growth in the regions of North America and Western Europe, owing to favourable regulations and affordability. Although the use of digital pathology in primary diagnosis is restricted in the U.S., robust adoption across research centres has provided an impetus to the market in the country.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-124

According to FMI’s report, Asian countries are facing challenges in adopting digital pathology solutions owing to high cost structure, complexity in practical implementation of cloud-based digital pathology systems, and a general lack of awareness about digital pathology systems.

FMI’s report has segmented the digital pathology market on the basis of components, screening services, and end-users. The report also offers region-wise forecast and analysis on the key companies operating in the digital pathology landscape.

On the basis of components, the digital pathology market is broadly segmented into hardware, software and services.

The hardware segment includes scanner and other platform technologies, which currently accounts for major share of the global market. The software segment comprises on-premises software and cloud-based software. The on-premises software solution sub-segment has been estimated to account for largest share in the overall digital pathology software market in 2015.

On the basis of screening services, the histopathology screening segment has been estimated to account for 81% share of the overall digital pathology market in 2015. This is attributed to increasing usage of digital pathology systems in cancer research for histopathology screening of test samples.

On the basis on end user, the research centre segment is estimated to remain dominant in the global digital pathology market over the forecast period, owing to higher adoption among drug discovery and development industry, which includes, research centres, contract research organisation and others. This segment has been estimated to account for 63% share of the overall digital pathology market revenue in 2015.

Key trends identified in the digital pathology market include use of digital pathology as second-opinion collaboration technology in cancer treatment, increasing research activities in personalized medicines, and integration of LIS, LIMS and EMR solution with digital pathology.

Implementation of image lifecycle management, disaster recovery solutions, tiered storage management plans in data management in on-premises as well as cloud-based solution are driving the adoption of digital pathology in the healthcare sector globally.

Leading Companies in Digital Pathology Market

Key market players covered in the report include Perkin Elmer, Inc., MedImmune, LLC (AstraZeneca), Sectra AB, Koninklijke Philips N.V, GE Healthcare, Inspirata Co., Ventana Medical Systems, Inc., Leica Biosystems, 3D-Histech Ltd, Hamamatsu Photonics, K.K., Digipath Co., ZEISS, Olympus Corporation, and Yokogawa Electronic Corporation.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-124

These leading players are bolstering their position through product launches and acquisitions as a key development strategy in order to sustain their position in the competitive market. The Tier 1 companies are focusing on a collaborative approach with cloud service providers to provide overall service to end-users.

Contrast Media Injectors Market to expand at a CAGR of 5.6% by 2025

Future Market Insights (FMI), in its latest report titled ‘Contrast Media Injectors Market: Global Industry Assessment and Forecast, 2015-2025’, has projected the global contrast media injectors market revenue to expand at a CAGR of 5.6% during the forecast period (2015-2025).

The global contrast media injectors market was valued at US$ 979.5 Mn and accounted for 3.0% share of the global diagnostics imaging devices market in 2014. Revenue contribution of contrast media injectors market to the global diagnostics imaging devices market is expected to increase to US$ 1,773.4 Mn by the end of 2025, expanding at a CAGR of 5.6% in terms of value during the forecast period. Continuous adoption of contrast media injectors for contrast media insertion owing to benefits on offer such as increased patient safety, reduced contrast media wastage and increasing demand for early diagnosis of chronic diseases are expected to positively affect growth of the contrast media injectors market across the globe. Global contrast media injectors market has been estimated to be valued at US$ 1,029.2 Mn in 2015, mainly driven by increasing adoption of contrast media injectors in the field of oncology and cardiology.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-823 

The report analyses the global contrast media injectors market in terms of market value (US$ Mn) and market volume (units) by product, region and end user, and provides information regarding market dynamics, competitive landscape, current trends, market estimation and forecast.

Adoption rate of contrast media injectors amongst physicians has increased significantly, owing to technological advancements and benefits such as superior prognosis of medical condition due to enhanced quality of images obtained post contrast media insertion. Emergence of alternative techniques for diagnosis of disease such as cancer and side effects caused due to contrast media are certain factors that are expected to hamper growth of the global contrast media injectors market to a certain extent. Major trends in the contrast media injectors market include increased adoption of syringeless contrast media injectors for reduction of contrast media wastage, introduction of advanced software to make the device more user friendly and consistent investment in research and development.

North America dominated the contrast media injectors market with over 33.5% share in terms of value in 2014, and is expected to remain dominant throughout the forecast period. The contrast media injectors market in APEJ and Japan are expected to register robust CAGRs of 5.7% and 5.8% respectively, in terms of value, during the forecast period. Western Europe and Eastern Europe are expected to lose revenue share over the forecast period, as contrast media injectors market is relatively mature in these regions due to increasing adoption of alternative techniques for diagnosis of chronic diseases.

On the basis of product type, contrast media injectors market is segmented into CT injectors, MRI injectors and cardiology injectors. In terms of volume growth, CT injectors segment is expected to account for the maximum share in the market. MRI injectors segment is expected to register highest CAGR over the forecast period, in terms of volume. CT injectors segment is expected to dominate the global contrast media injectors market, in terms of revenue, owing to increasing adoption of combination systems. In terms of volume and value, cardiology injectors segment is expected to register lowest CAGR over the forecast period.

On the basis of end user, contrast media injectors market is segmented into hospitals, ambulatory surgical centres and diagnostics centres. In terms of value and volume, diagnostics centres segment is expected to register lowest CAGR during the forecast period. Hospitals segment revenue growth is majorly driven by increasing installations of imaging modalities in hospitals. Increasing adoption of contrast media injectors among physicians for early diagnosis of chronic disease, especially in the field of oncology and cardiology is fueling revenue growth of the contrast media injectors market.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-823

Some of the key market participants included in the report are Mallinckrodt, Guerbet SA, Bayer AG, Bracco Imaging S.p.A., Ulrich GmbH & Co. KG., Medtron AG and Nemoto Kyorindo Co. Ltd.

Increasing out-of-pocket healthcare expenditure and patent expiries of blockbuster drugs fuelling the global branded generics market

A recent research conducted by Future Market Insights predicts that the global market for branded generics will witness a steady growth in terms of revenues. Over a ten-year forecast period from 2016 to 2026, the size of global branded generics market has been estimated to expand at a steady CAGR of 7.3%. Brand-name prescriptions will continue to be ubiquitous among aged people in the world, and since geriatric demographics account for a large portion of global drug-consuming population, demand for branded generics will also rise substantially. In 2016, the global branded generics market has been valued at nearly US$ 200 billion, and is projected to reach US$ 413.8 Bn market valueby the end of forecast period.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-1260

Some of the leading manufacturers of branded generics are based in Asian countries, and are extending their production capacity to keep up with the surging global depend. In Asia-Pacific excluding Japan (APEJ) region, about US$ 150 billion revenues are expected to be procured by the end of 2026. During the forecast period, branded generics market in the APEJ region will attain fastest growth, registering a 10% CAGR, contributing over 35% of global branded generics revenues. North America, Eastern Europe and Latin America are also expected to be lucrative for growth of branded generics sales, while revenues in Western Europe, Japan and Middle East & Africa (MEA) are likely to incur a considerable dip by 2026-end.

Competitive Timeline in Global Branded Generics Market

• Since 2015, Abbott Laboratories, a leading drugmaker in the global pharmaceuticals industry, has aimed at capitalizing from branded generics businesses in developing regions.
• Teva Pharmaceuticals acquired Allergan’s branded generics vertical, while Pfizer Inc. bought Hospira Inc. – both acquisitions have been strategically carried out for repositioning market standings of Teva and Pfizer respectively.
• In December 2016, India-based Sun Pharmaceuticals Industries Ltd. agreed to buy Swiss drugmaker Novartis AG’s branded generics portfolio on cancer medications.
• Another leading branded generics manufacturer, Mylan N.V. recently launched anti-allergy devices which are expected to be half the price of its branded EpiPens.
• Other prominent companies partaking in the growth of global branded generics market include, Aspen Pharmacare Holding Ltd. and Valeant Pharmaceuticals International, Inc.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-1260

Research Highlights on Global Branded Generics Market

The report includes a segmental analysis of the global branded generics market, fragmenting its growth on the type of drug formulation, major drug classes, therapeutic applications, and distribution channels. Based on such segmentation, some of the key findings compiled in the report are:

• Nearly three-fifth of the global branded generics revenues estimated in 2016 are expected to be accounted by oral-type formulations, with parenteral, topic and other formulation types collectively accounting for 8% market value share.
• Hospital pharmacies & retail pharmacies will remain as the largest distribution channels for branded generics throughout the globe.
• In 2016 and beyond, the demand for branded generics in therapeutic treatment of cardiovascular diseases will be significant, revenues from which are expected to increase at more than 8% CAGR over the forecast period.
• Global revenues of branded generics accounted by anti-hypertensive drug class are predicted to surpass US$ 25 billion by 2026-end.